In conclusion, we successfully identified MDM2 as a potential therapeutic target for wtTP53‐RTK NSCLC via a genome‐wide CRISPR/Cas9 screen and confirmed the therapeutic potential using a small molecular inhibitor RG7388, both as a single agent or in combination with chemotherapeutic drugs. Here, MDM2 is linked to non-small cell lung carcinoma.